The proliferative and apoptotic landscape of basal-like breast cancer
Basal-like breast cancer (BLBC) is an aggressive molecular subtype that represents up to 15% of breast cancers. It occurs in younger patients, and typically shows rapid development of locoregional and distant metastasis, resulting in a relatively high mortality rate. Its defining features are that it is positive for basal cytokeratins and, epidermal growth factor receptor and/or c-Kit. Problematically, it is typically negative for the estrogen receptor and human epidermal growth factor receptor 2 (HER2), which means that it is unsuitable for either hormone therapy or targeted HER2 therapy. As a result, there are few therapeutic options for BLBC, and a major priority is to define molecular subgroups of BLBC that could be targeted therapeutically. In this review, we focus on the highly proliferative and anti-apoptotic phenotype of BLBC with the goal of defining potential therapeutic avenues, which could take advantage of these aspects of tumor development.
|Authors||Alexandrou, S.; George, S. M.; Ormandy, C. J.; Lim, E.; Oakes, S. R.; Caldon, C. E.|
|Responsible Garvan Author||A/Prof Liz Caldon|
|Publisher Name||INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/30720718|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/14985|